Aperio Group’s NextGen Healthcare, Inc. Common Stock NXGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
$499K Sell
27,336
-145
-0.5% -$2.3K ﹤0.01% 1971
2020
Q3
$350K Sell
27,481
-2,382
-8% -$30.4K ﹤0.01% 2000
2020
Q2
$328K Buy
29,863
+586
+2% +$6.07K ﹤0.01% 1981
2020
Q1
$306K Buy
29,277
+17,399
+146% +$224K ﹤0.01% 1891
2019
Q4
$191K Sell
11,878
-480
-4% -$7.93K ﹤0.01% 2208
2019
Q3
$194K Sell
12,358
-5,242
-30% -$87.2K ﹤0.01% 2173
2019
Q2
$350K Buy
17,600
+2,183
+14% +$40.8K ﹤0.01% 1953
2019
Q1
$259K Buy
15,417
+3,348
+28% +$58.1K ﹤0.01% 2067
2018
Q4
$183K Hold
12,069
﹤0.01% 2155
2018
Q3
$242K Sell
12,069
-91
-0.7% -$1.93K ﹤0.01% 2112
2018
Q2
$237K Buy
+12,160
New +$192K ﹤0.01% 2104
2016
Q2
Sell
-10,686
Closed -$163K 2042
2016
Q1
$163K Buy
+10,686
New +$162K ﹤0.01% 1912
2015
Q3
Sell
-16,421
Closed -$272K 2020
2015
Q2
$272K Buy
16,421
+1,943
+13% +$31.3K ﹤0.01% 1696
2015
Q1
$231K Buy
+14,478
New +$239K ﹤0.01% 1741

Other funds holding NXGN

Aperio Group's NXGN Position: Q4 2020 in Review

Aperio Group reduced its NextGen Healthcare, Inc. Common Stock (NXGN) stake by 0.53% in Q4 2020, selling an estimated $2.3K and leaving 27,336 shares worth $499K. The position accounts for ﹤0.01% of the portfolio, ranked #1971.

Aperio Group first reported a position in NXGN in Q1 2015 and has held it in 14 quarters since. 152 funds tracked by Wall St. Rank hold NXGN as of Q4 2020.

  • Aperio Group held 27,336 shares of NextGen Healthcare, Inc. Common Stock worth $499K as of Q4 2020.
  • Aperio Group sold 145 NextGen Healthcare, Inc. Common Stock shares in Q4 2020, an estimated $2.3K.
  • NextGen Healthcare, Inc. Common Stock made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1971 holding.
  • Aperio Group first reported a position in NextGen Healthcare, Inc. Common Stock in Q1 2015 and has held it in 14 quarters since.
  • 152 funds tracked by Wall St. Rank held NextGen Healthcare, Inc. Common Stock as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.